clinical topic updates

Accuracy of Prognostic Factors for Patients With Rheumatoid Arthritis

by James O’Dell, MD, MACR, MACP

Overview

A number of prognostic factors have been identified that are associated with clinical outcomes in patients with rheumatoid arthritis (RA). Our featured expert discusses the accuracy and utility of prognostic factors and how to incorporate them into the routine management of patients with RA.

Expert Commentary

James O’Dell, MD, MACR, MACP

Stokes Shackleford Distinguished Professor
Chief, Division of Rheumatology and Vice Chair for Education, Department of Internal Medicine
Director, Internal Medicine Residency Program
University of Nebraska Medical Center
Founder and Director, Rheumatoid Arthritis Investigational Network
Omaha, NE

“The main prognostic factor that I use in the management of patients who have already started treatment is the number of tender and swollen joints. If a patient still has tender/swollen joints even after he or she has started a particular therapy, I know that a change of therapy is indicated.”

James O’Dell, MD, MACR, MACP

Various prognostic factors for poor outcome have been identified in patients with RA, but poor prognostic factors are most applicable to the untreated natural history of the disease. The most reliable prognostic factor is anti-cyclic citrullinated peptide (anti-CCP) antibody positivity, which is observed in approximately 75% of patients with RA and suggests not only that the patient really has RA but also aggressive erosive disease. Further, those who are double positive for both anti-CCP antibody and rheumatoid factor (RF) and who have joint erosions have particularly aggressive disease; these individuals require aggressive therapy and will have poor clinical outcomes if they do not receive appropriate treatment. Even double-positive patients, however, have a good prognosis if they are treated appropriately, so it is important to treat all patients early and aggressively once they have been diagnosed with RA. The medical community has learned over the last 20 years that all individuals with RA should be treated to a target of low disease activity or remission, regardless of their baseline prognostic indicators. If patients can achieve a low disease activity, they will do extremely well. When I see patients with new-onset RA, I am actually encouraged if they are anti-CCP positive because I know exactly what is wrong with them and I feel confident in my ability to help them achieve remission with the appropriate and well-tolerated medications.

Data indicate that patients who are negative for anti-CCP and RF have a better overall prognosis, yet we also know that seropositive patients are precisely the patients for whom certain biologicals work best. The real challenge is identifying the right medication for each individual because none of the prognostic factors have been shown, to date, to be useful for guiding treatment decisions and predicting which medication is the most appropriate for any individual patient. The main prognostic factor that I use in the management of patients who have already started treatment is the number of tender and swollen joints. If a patient still has tender/swollen joints even after he or she has started a particular therapy, I know that a change of therapy is indicated. An important goal of future research is to identify prognostic factors that can predict a patient’s differential response to therapies. When we are able to do this, RA therapy will take a huge leap forward.

References

Bird P, Nicholls D, Barrett R, et al; OPAL Consortium. Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study. Int J Rheum Dis. 2017;20(4):460-468.

O’Dell JR. Treatment of rheumatoid arthritis. In: Firestein GS, Rudd RC, Gabriel SE, McInnes IB, O’Dell JR, eds. Kelley & Firestein’s Textbook of Rheumatology, 10th ed. Philadelphia, PA: Elsevier Saunders; 2017: 1187-1212.

Sokolove J, Johnson DS, Lahey LJ, et al. Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol. 2014;66(4):813-821.

Whiting PF, Smidt N, Sterne JA, et al. Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med. 2010;152(7):456-464.

More in Rheumatoid Arthritis

Thumb

Rheumatoid Arthritis

Clinically Meaningful Improvement in Patient-Reported Outcomes With Interleukin-6 Inhibition

Clinical Study Insights by Daniel E. Furst, MD

Clinical Study Title:Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour n...READ MORE

Thumb

Rheumatoid Arthritis

Recommended Treatment of Patients With Rheumatoid Arthritis and Comorbidities Such as Liver Impairment, Chronic Kidney Disease, or Interstitial Lung Disease

Patient Care Perspectives by James O’Dell, MD, MACR, MACP

All of the anti–rheumatoid arthritis (RA) agents may be associated with hepatic effects. Methotrexate (MTX), in particular, is contraindicated in p...READ MORE

Thumb

Rheumatoid Arthritis

Appropriate Use of Biologics in Rheumatoid Arthritis Based on Recent Guidelines

Expert Roundtables by Jonathan S. Hausmann, MD, James O’Dell, MD, MACR, MACP, Alvin F. Wells, MD, PhD

Earlier use of biologics is a point of contention in the field of rheumatology, but there is no discord on the overarching goal of achieving rapid ...READ MORE

More In Rheumatology

Systemic Lupus Erythematosus

Low-Dose Interleukin 2 and Its Potential in Systemic Lupus Erythematosus

Patient Care Perspectives
by George C. Tsokos, MD

Systemic Lupus Erythematosus

Interferon-Blocking Strategies in Systemic Lupus Erythematosus Research

Clinical Topic Updates
by Joan T. Merrill, MD

Systemic Lupus Erythematosus

Targeted Biologic Therapy in Systemic Lupus Erythematosus

Expert Roundtables
by Bevra H. Hahn, MD; Joan T. Merrill, MD; and George C. Tsokos, MD